Hemab Therapeutics
NASDAQ: COAGIncorporated in Delaware · 5 known investors
Hemab develops targeted therapies for bleeding and clotting disorders such as Glanzmann thrombasthenia, Factor VII deficiency, Von Willebrand Disease, and heavy menstrual bleeding. The company uses biologics and precision-designed therapeutic candidates to stabilize coagulation proteins and prevent bleeding events.
Investors · 5
Competitors · 2
by search overlapBioworld14 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Adimab13 shared keywordsAdimab develops proprietary platforms for antibody and protein therapeutic discovery, engineering fully-functional immunoglobulins in a controllable in vitro eukaryotic system. The company partners with biopharma firms to accelerate the development of transformative protein therapeutics from discovery through clinical progression.
Companies competing with Hemab Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does Hemab Therapeutics do?
- Hemab develops targeted therapies for bleeding and clotting disorders such as Glanzmann thrombasthenia, Factor VII deficiency, Von Willebrand Disease, and heavy menstrual bleeding. The company uses biologics and precision-designed therapeutic candidates to stabilize coagulation proteins and prevent bleeding events.
- Who are Hemab Therapeutics's investors?
- Hemab Therapeutics's investors include Access Biotechnology, Avoro Capital Advisors, HealthCap, Novo Holdings, Sofinnova Partners.